Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice

Edward A. Stadtmauer, Keith M. Sullivan, Mohamed El Idrissi, Bruno Salaun, Aránzazu Alonso Alonso, Charalambos Andreadis, Veli-Jukka Anttila, Adrian JC Bloom, Raewyn Broady, Claudia Cellini, Antonio Cuneo, Alemnrew F. Dagnew, Emmanuel Di Paolo, HyeyeonSeok Eom, Ana Pilar González-Rodríguez, Andrew Grigg, Andreas Gunther, Thomas C. Heineman, Isidro Jarque, Jae-Yong Kwak, Alessandro Lucchesi, Lidia Oostvogels, Marta Polo Zarzuela, Anne E. Schuind, Thomas C. Shea, Ulla Marjatta Sinisalo, Filiz Vural, Lucrecia Yáñez San Segundo, Pierre Zachée, and Adriana Bastidas for the ZOE-SCT study group collaborators

ABSTRACT
Immunocompromised individuals, particularly autologous hematopoietic stem cell transplant (auHSCT) recipients, are at high risk for herpes zoster (HZ). We provide an in-depth description of humoral and cell-mediated immune (CMI) responses by age (protocol-defined) or underlying disease (post-hoc) as well as efficacy by underlying disease (post-hoc) of the adjuvanted recombinant zoster vaccine (RZV) in a randomized observer-blind phase III trial (ZOE-HSCT, NCT01610414). 1846 adult auHSCT recipients were randomized to receive a first dose of either RZV or placebo 50–70 days post-auHSCT, followed by the second dose at 1–2 months (M) later. In cohorts of 114–1721 participants, at 1 M post-second vaccine dose: Anti-gE antibody geometric mean concentrations (GMCs) and median gE-specific CD4[2+] T-cell frequencies (CD4 T cells expressing ≥2 of four assessed activation markers) were similar between 18–49 and ≥50-year-olds. Despite lower anti-gE antibody GMCs in non-Hodgkin B-cell lymphoma (NHBLCL) patients, CD4[2+] T-cell frequencies were similar between NHBLCL and other underlying diseases. The proportion of polyfunctional CD4 T cells increased over time, accounting for 79.6% of gE-specific CD4 T cells at 24 M post-dose two. Vaccine efficacy against HZ ranged between 42.5% and 82.5% across underlying diseases and was statistically significant in NHBLCL and multiple myeloma patients. In conclusion, two RZV doses administered early post-auHSCT induced robust, persistent, and polyfunctional gE-specific immune responses. Efficacy against HZ was also high in NHBLCL patients despite the lower humoral response.

PLAIN LANGUAGE SUMMARY
What is the context?
• After haematopoietic stem cell transplantation, patients have impaired immunity from conditioning chemotherapy regimens, often exacerbated by underlying diseases, putting them at high risk of developing herpes zoster. In this population, antiviral prophylaxis is the current standard of care to reduce herpes zoster risk. Vaccination provides an additional means to prevent herpes zoster. Live-attenuated vaccines are generally contraindicated in immunocompromised patients. A non-live, adjuvanted recombinant zoster vaccine (RZV, Shingrix, GSK), has been approved for use in adults 250 years of age in the European Union, United States, Canada, Australia, Japan, and China. This vaccine is highly efficacious at preventing herpes
zoster in adults over 50 years of age, as demonstrated in large, placebo-controlled randomised trials. Importantly, Shingrix use is not contraindicated in immunocompromised conditions, and was found to be highly efficacious in adults who had recently undergone autologous haematopoietic stem cell transplant.

**What is new?**

- In autologous haematopoietic stem cell transplant recipients in whom Shingrix has demonstrated efficacy, two doses elicited high and persistent immune responses. Date presented here further support our understanding of the impact of specific factors such as age or underlying diseases on the vaccine’s effect in the population studies, as well as the characteristics of the elicited cell-mediated immune responses.

**What is the impact?**

- These results indicate that Shingrix, given shortly after haematopoietic stem cell transplant, can induce robust immune responses and reduce the risk of herpes zoster, even in individuals with immunosuppression due to underlying disease and/or use of immunosuppressive therapies, regardless of age or underlying disease.

---

**Introduction**

Herpes zoster (HZ) develops following the reactivation of latent varicella-zoster virus (VZV), particularly in individuals with reduced immune function, such as older adults, and in persons with acquired immunodeficiency or receiving immunosuppressive therapies.\(^1\)\(^2\). It also commonly occurs in patients who have undergone allogeneic, syngeneic, or autologous haematopoietic stem cell transplant (HSCT), in whom T-cell immunity is diminished (incidence range: 16–30%).\(^3\)\(^4\)

To prevent virus-associated infections, including HZ, antiviral prophylaxis is commonly administered to patients after HSCT.\(^7\)\(^8\) However, the efficacy of the prophylaxis is impacted by the adherence to medication and its duration and HZ risk increases once prophylaxis has been stopped.\(^8\)\(^9\)\(^10\)

Improved prevention strategies to provide sustained protection against HZ are therefore needed.\(^8\) Vaccination can provide long-term protection, but live-attenuated vaccines are contraindicated in immunocompromised individuals due to the risk of disseminated disease.\(^11\)\(^12\)

An adjuvanted recombinant zoster vaccine (RZV, Shingrix, GSK) demonstrated >90% vaccine efficacy against HZ in phase III clinical trials conducted in participants aged ≥50 and ≥70 years,\(^13\)\(^14\) and was first licensed in 2017 for use in adults aged ≥50 years.\(^15\) Another study showed that immune responses to RZV persist at least ten years in adults vaccinated at age ≥60 years and modeling predicts that these will persist for up to 20 years.\(^16\) As this is a non-live, recombinant subunit vaccine, there is no risk of it causing disseminated HZ in immunocompromised individuals, and RZV could represent an important strategy to prevent HZ in HSCT patients.

Due to diminished immunity following HSCT conditioning regimens, or due to the underlying malignancy, patients may be unable to mount an adequate protective immune response to vaccination given shortly after transplantation.\(^17\) Nevertheless, autologous HSCT patients aged ≥18 years showed strong glycoprotein E (gE)-specific humoral and CMI responses to RZV in a phase I/IIa study and a phase III efficacy study (ZOE-HSCT)\(^18\)\(^19\). In ZOE-HSCT, RZV administered 50–70 days post-transplant, demonstrated 68% efficacy (95% confidence interval [CI] 56–78) in preventing HZ and induced robust gE-specific humoral and CMI responses.\(^19\) Here we further characterize gE-specific humoral and CMI responses by age and underlying diseases, and also present vaccine efficacy according to underlying diseases in the ZOE-HSCT study population.

**Materials and methods**

**Study design**

This was a randomized, observer-blind, placebo-controlled, parallel-group phase III study, conducted in 167 centers in 28 countries (NCT01610414). The study protocol was reviewed and approved by relevant Institutional Review Boards or Independent Ethics Committees. The full study protocol is available as part of the primary publication.\(^19\)

**Participants**

Eligible adults aged ≥18 years had undergone autologous HSCT 50–70 days before the first dose of study vaccine. Detailed inclusion and exclusion criteria have been described previously.\(^19\) Before study start, all participants provided written informed consent.

**Randomization and masking**

All eligible participants were randomized 1:1 to receive either RZV or placebo using a minimization procedure, which has been previously described.\(^19\) At designated centers, participants were further randomly allocated to the humoral and CMI subcohorts until the sub-cohort targets were reached. The CMI sub-cohort included participants from Belgium, France, Japan, Spain, and the United States, who were enrolled at centers that had access within 24 hours from collection time to a peripheral blood mononuclear cell processing facility validated by GSK. The humoral immunity sub-cohort included participants from both the CMI sub-cohort and additional participants from designated centers in Australia, Canada, and Korea.

Vaccine/placebo doses were administered by unmasked study staff who did not participate in the study assessments. Further details on blinding undertaken for the assessment of efficacy have been presented previously.\(^19\)
**Procedures**

Each 0.5 ml RZV dose contained recombinant VZV gE (50 μg) and the AS01b adjuvant system (containing MPL, QS21, and liposome). Placebo contained lyophilized sucrose reconstituted in 0.9% saline solution. The first dose was administered 50–70 days post-transplantation and the second dose one to two months (M) thereafter.

**Outcomes**

 Vaccine efficacy against HZ (primary study outcome), HZ complications, and HZ-related hospitalizations, as well as safety and overall immunogenicity results, have been described previously. Here we present humoral and CMI responses by age (18–49 years and ≥50 years), which were assessed in protocol-defined sub-group analyses. Vaccine efficacy against HZ and immunogenicity of RZV by underlying disease (multiple myeloma [MM], non-Hodgkin B-cell and T-cell lymphoma [NHBCL, NHTCL], Hodgkin lymphoma [HL], acute myeloid leukemia [AML], and solid malignancies and others), as well as polyfunctional gE-specific CD4 T-cell responses were assessed post-hoc.

**Assessments**

Assessment of HZ cases and estimation of vaccine efficacy have been described in detail previously (Supplementary Text 1). Blood samples (8 ml) were collected from all participants at pre-vaccination and 1 M post-dose two to contribute to the correlate of protection assessment (not reported here). These blood samples were used to evaluate humoral immunogenicity according to underlying diseases, which are described herein. Additional blood samples (8 ml) were taken from the humoral immunogenicity sub-cohort at 1 M post-dose one, and at 12 M and 24 M post-dose two. Participants in the CMI sub-cohort provided additional 30 ml blood samples at all five predefined study visits.

Anti-glycoprotein E (gE) antibody concentrations were measured using a previously described assay. The frequency of gE-specific CD4 T cells expressing at least two of the following activation markers (CD4[2+] T cells) per 10⁶ CD4 T cells was calculated: interferon-γ (IFN-γ), interleukin-2 (IL-2), tumor necrosis factor-α (TNF-α), and CD40 ligand (CD40L). For the analysis of gE-specific T-cell polyfunctionality, the frequency of CD4 T cells expressing one or any combination of two, three, or four of the four activation markers assessed was calculated. Additional details have been disclosed previously, and are as described in Supplementary Text 2.

**Statistical analysis**

All endpoints presented here are descriptive. Therefore, no formal sample size calculations were performed for these analyses.

Post-hoc vaccine efficacy evaluation and analyses of humoral immunity according to underlying diseases were performed on the modified total vaccinated cohort, which included all participants who received both doses and did not develop HZ before 1M post-dose two. Humoral immune responses according to underlying diseases were evaluated in the modified total vaccinated cohort (from samples collected for the correlate of protection assessment, which is not reported here) rather than in the according-to-protocol immunogenicity sub-cohort to provide a greater sample size in each subgroup.

Humoral immune responses per age and CMI responses per age and underlying diseases were assessed in the according-to-protocol immunogenicity cohorts, which included all eligible participants from the humoral and CMI sub-cohorts, respectively, who received both doses, complied with the protocol and had available immunogenicity endpoint measurements.

Anti-gE antibody geometric mean concentrations (GMCs) and their 95% CIs were determined. The vaccine response in terms of anti-gE antibody concentration (i.e., humoral vaccine response) was defined as a ≥4-fold increase in the anti-gE antibody concentration compared either with the pre-vaccination concentration (initially seropositive participants) or with the anti-gE antibody cutoff value for seropositivity (97 milli-International Units per milliliter [mIU/mL] (initially seronegative participants).

The vaccine response in terms of CD4[2+] T cell frequency (i.e., CMI vaccine response) was defined as a ≥2-fold increase in the frequency of CD4[2+] T cells, as compared to pre-vaccination frequency (for participants with pre-vaccination CD4[2+] T-cell frequency ≥320 per 10⁶ CD4 T cells counted) or the cutoff (for participants with pre-vaccination frequencies below the cutoff).

Exact 95%CI were computed at each time point for the humoral and CMI vaccine response rate using the Clopper Pearson exact method. The 95%CI for the GMCs was computed by anti-log transformation of the 95%CI for the mean of log-transformed concentrations.

The statistical analyses were performed using SAS Drug Development.

**Results**

**Study population**

Characteristics of the overall study population, as well as reasons for withdrawals from the modified total vaccinated cohort have been previously published. Of the 1846 participants (RZV: 922, placebo: 924) vaccinated between 13 July 2012 and 31 July 2015, 1721 (RZV: 870, placebo: 851) were included in the modified total vaccinated cohort and 158 (RZV: 82, placebo: 76) were included in according-to-protocol cohort for humoral immunogenicity at 1M post-dose two, of whom 114 (RZV: 59, placebo: 55) were also included in the according-to-protocol cohort for CMI at 1M post-dose two (Figure 1).

The demographic characteristics were balanced between the RZV and placebo groups in all cohorts evaluated (Table 1) and comparable to the TVC. Most participants were white, male, and aged ≥50 years, and MM and NHBCL were the predominant underlying diseases.

**Immune responses according to age**

Before vaccination, ≥82.4% of participants were seropositive for anti-gE antibody across age cohorts and study groups. In
RZV group participants aged 18–49 and ≥50 years, respectively, the humoral vaccine response rate was 57.7% (95% CI 36.9–76.6) and 71.4% (57.8–82.7) at 1 M post-dose two and 23.1% (5.0–53.8) and 56.0% (34.9–75.6) at 24 M post-dose two. In placebo group participants, the humoral vaccine response rate was ≤22.2% across age cohorts and time points. In RZV group participants aged 18–49 and ≥50 years, respectively, the anti-gE antibody GMCs were 1011.0 (95%CI 629.7–1623.2) and 669.3 (460.2–973.5) mIU/mL at pre-vaccination, 12523.4 (4950.7–31679.7) and 12861.3 (7366.4–22455.0) mIU/mL at 1 M post-dose two, and 1492.5 (466.3–4777.1) and 4025.0 (1597.6–10140.1) mIU/mL at 24 M post-dose two. In both age cohorts of the placebo group, median anti-gE antibody GMCs remained near pre-vaccination levels up to and including the last assessment (Figure 2(c,d), Supplementary Table 2).

Immune responses according to underlying diseases

In the RZV group, the humoral vaccine response rate at 1 M post-dose two was lower among NHBC patients (14.2%, 95% CI 9.9–19.4) compared to patients with any of the other underlying diseases (≥69.6%). In the placebo group, the humoral vaccine response rate was ≤3.0% across underlying diseases at 1 M post-dose two. In the RZV group, anti-gE antibody GMCs increased substantially (i.e., >9-fold) at 1 M post-dose two compared to pre-vaccination irrespective of the underlying...
Table 1. Baseline demographic characteristics (modified total vaccinated cohort and according-to-protocol cohorts for humoral and cell-mediated immunogenicity).

| Characteristic                        | According-to-protocol cohort | Modified total vaccinated cohort, N = 1721 | Humoral immunity sub-cohort, N = 158 | Cell-mediated immunity sub-cohort, N = 114 |
|--------------------------------------|-----------------------------|------------------------------------------|-------------------------------------|------------------------------------------|
|                                      | RZV (N = 870) | Placebo (N = 851) | RZV (N = 82) | Placebo (N = 76) | RZV (N = 59) | Placebo (N = 55) |
| Age (years)                          |                |                           |                           |                                  |                                  |                  |
| Mean ± SD                            | 54.9 ± 11.5    | 55.1 ± 11.3                | 54.2 ± 11.8 | 56.5 ± 9.9   | 54.2 ± 10.5 | 55.6 ± 9.9     |
| Age group-no. (%)                    |                |                           |                           |                                  |                                  |                  |
| 18–49 years                          | 213 (24.5)     | 212 (24.9)                 | 26 (31.7) | 17 (22.4)    | 20 (33.9) | 14 (25.4)       |
| ≥50 years                            | 657 (75.5)     | 639 (75.1)                 | 56 (68.3) | 59 (77.6)    | 39 (66.1) | 41 (74.6)       |
| Gender-no. (%)                       |                |                           |                           |                                  |                                  |                  |
| Female                               | 323 (37.1)     | 317 (37.3)                 | 29 (35.4) | 29 (38.2)    | 18 (30.5) | 23 (41.8)       |
| Male                                 | 547 (62.9)     | 534 (62.7)                 | 53 (64.6) | 47 (61.8)    | 41 (69.5) | 32 (58.2)       |
| Race-no. (%)                         |                |                           |                           |                                  |                                  |                  |
| White                                | 686 (78.9)     | 666 (78.3)                 | 60 (73.2) | 58 (76.3)    | 48 (81.4) | 47 (85.5)       |
| Black                                | 15 (1.7)       | 23 (2.7)                   | 3 (3.7)  | 1 (1.3)      | 3 (5.1)  | 1 (1.8)         |
| Asian                                | 138 (15.9)     | 139 (16.3)                 | 17 (20.7) | 16 (21.1)    | 6 (10.2) | 6 (10.9)        |
| Other                                | 31 (3.6)       | 23 (2.7)                   | 2 (2.4)  | 1 (1.3)      | 2 (3.4)  | 1 (1.8)         |
| Underlying disease-no. (%)           |                |                           |                           |                                  |                                  |                  |
| Multiple myeloma                     | 472 (54.3)     | 465 (54.6)                 | 44 (53.7) | 42 (55.3)    | 33 (55.9) | 32 (58.2)       |
| Other diseases                       | 398 (45.7)     | 386 (45.4)                 | 38 (46.3) | 34 (44.7)    | 26 (44.1) | 23 (41.8)       |
| Non-Hodgkin B-cell lymphoma          | 237 (27.2)     | 244 (28.7)                 | .        | .           | 16 (27.1) | 12 (21.8)       |
| Non-Hodgkin T-cell lymphoma          | 43 (4.9)       | 40 (4.7)                   | .        | .           | 3 (5.1)  | 3 (5.5)         |
| Hodgkin lymphoma                     | 74 (8.5)       | 60 (7.1)                   | .        | .           | 1 (1.7)  | 3 (5.5)         |
| Acute myeloid leukemia               | 20 (2.3)       | 16 (1.9)                   | .        | .           | 2 (3.4)  | 2 (3.6)         |
| Solid malignancies and others        | 24 (2.8)       | 26 (3.1)                   | .        | .           | 4 (6.8)  | 3 (5.3)         |
| Other hematologic malignancies       | 10             | 9                          | .        | .           | 1        | 2               |
| Amyloidosis                          | 7              | 7                          | .        | .           | 1        | 0               |
| Solid malignancies                   | 6              | 6                          | .        | .           | 2        | 0               |
| Systemic sclerosis                   | 1              | 3                          | .        | .           | 0        | 1               |
| Multiple sclerosis                   | 0              | 1                          | .        | .           | 0        | 0               |

N = number of participants included in each group; no. (%) = number (percentage) of participants in each category; SD = standard deviation; RZV = adjuvanted recombinant zoster vaccine.

Figure 2. Humoral and cell-mediated immune responses according to age (according-to-protocol cohort for humoral immunogenicity). CMI = cell-mediated immunity; M = month; N = number of participants with available results; Q1, Q3 = first and third quartiles; RZV = adjuvanted recombinant zoster vaccine; In panels A–C, error bars depict two-sided exact 95% confidence intervals.

disease with the exception of NHBCL (<2-fold increase). No increases were observed in placebo recipients (Figure 3(a,b), Supplementary Table 3).

Due to the relatively limited size of the CMI sub-cohort, at each time point, few participants with underlying diseases other than MM or NHBCL had available data. In the RZV group, the
CMI vaccine response rate ranged between 87.5% (95% CI 67.6–97.3) in MM patients and 100% in patients with NHBCL and each of the other underlying diseases at 1 M post-dose two. At 24 M post-dose two, the CMI vaccine response rate was 69.2% (38.6–90.9) in MM and 71.4% (29.0–96.3) in NHBCL patients. In the placebo group, the CMI vaccine response rate was 0.0% across underlying diseases at 1 M post-dose 2. At 24 M post-dose two, the CMI vaccine response rate ranged between 0.0% and 50.0% (1.3–98.7; one of two HL patients) across underlying diseases. In the RZV group, median CD4[2+] T-cell frequencies ranged between 18.3 (in NHBCL patients; interquartile range: 1.0–48.9) and 408.6 (1.0–816.3) at pre-vaccination, were highest at 1 M post-dose two across underlying diseases (3294.2 [in NHBCL patients; 2040.4–11857.2] to 21359.7 [19334.4–23385.1]), and ranged between 1691.0 (in MM patients; 579.5–3862.9) and 16573.2 (16573.2–16573.2) at 24 M post-dose two. No increases in median CD4[2+] T-cell frequencies were observed in placebo group participants with any of the underlying diseases (Figure 3(c,d), Supplementary Table 2).

**Polymodularity of gE-specific CD4 T-cell responses**

CD40L was the most commonly expressed marker at all time points, followed by IL-2. IFN-γ and TNF-α were usually expressed in combination with CD40L and/or IL-2. The frequencies of CD4 T cells expressing individual and combinations of activation markers were highest at 1 M post-dose two (peak of the measured response) and decreased thereafter (Figure 4).
Table 2. Vaccine efficacy (Poisson method) against first/only herpes zoster episode during the whole study per underlying disease (modified total vaccinated cohort).

| Type                                              | N  | n   | Cumulative follow-up | Number per 1000 person-years | N  | n   | Cumulative follow-up | Number per 1000 person-years | Vaccine efficacy % (95% CI) | p-Value |
|---------------------------------------------------|----|-----|----------------------|-------------------------------|----|-----|----------------------|-------------------------------|-------------------------------|---------|
| Multiple myeloma                                  | 472| 22  | 907.2                | 24.2                         | 465| 69  | 786.7                | 87.7                         | 72.35 (54.76–83.71)          | <0.0001 |
| Non-Hodgkin B-cell lymphoma                       | 237| 19  | 438.5                | 43.3                         | 244| 45  | 410.6                | 109.6                        | 60.46 (31.02–78.16)          | 0.0006  |
| Non-Hodgkin T-cell lymphoma                       | 43 | 1   | 78.9                 | 12.7                         | 40 | 5   | 69.2                 | 72.3                         | 82.45 (56.81–99.63)          | 0.1633  |
| Hodgkin lymphoma                                  | 74 | 5   | 136.9                | 36.5                         | 60 | 7   | 110.2                | 63.5                         | 42.50 (11.44–85.61)          | 0.5028  |
| Acute myeloid leukemia                             | 20 | 0   | 32.2                 | 0.0                          | 16 | 3   | 19.8                 | 151.4                        | 100 (48.86–100)              | 0.1105  |
| Solid malignancies and autoimmune diseases        | 24 | 2   | 39.4                 | 50.8                         | 26 | 6   | 35.4                 | 169.4                        | 70.00 (67.75–97.04)          | 0.2253  |

CI = confidence interval; N = number of participants included in each group; n = number of participants having at least one confirmed herpes zoster episode; RZV = adjuvanted recombinant zoster vaccine.

†Censored at the first occurrence of a confirmed herpes zoster episode and at the occurrence of treatment for relapse.

‡p-value = Two-sided exact p-value conditional to number of cases.

Compared to pre-vaccination, the proportion of CD4 T cells expressing only one activation marker decreased from 65.7% to 27.0% and 10.6% 1 M after RZV doses one and two, respectively, while the proportion of polyfunctional CD4 T cells (expressing three or four activation markers) increased from 19.1% to 55.1% and 69.0%, respectively. The proportion of polyfunctional CD4 T cells continued to increase up to 79.6% at 24 M post-dose two (Figure 5).

Vaccine efficacy according to underlying diseases

Vaccine efficacy against HZ was 72.4% (95% CI 54.8–83.7, \( p = .0001 \)) in MM and 60.5% (31.0–78.2, \( p = .0006 \)) in NHBLCL patients. Vaccine efficacy was also observed for all other underlying diseases (42.5%-100%), albeit not statistically significant (Table 2).

Discussion

Robust humoral and CMI responses were elicited in participants aged 18–49 and ≥50 years, with no major differences between the two age cohorts. While humoral immune responses declined to close to baseline levels in 18–49-year-olds through 24 M post-vaccination, CMI remained high in both age cohorts. Efficacy of RZV was similar in these two age cohorts,\(^a\) consistent with the fact that CMI responses are believed to be the main mechanistic driver for protection against HZ.\(^b\) The frequencies of gE-specific CD4[2+] T cells after vaccination in autologous HSCT patients aged ≥50 years were higher than those previously reported in immunocompetent adults aged ≥50 years, using the same assay.\(^c\) This may be explained by the proliferation triggered post-vaccination in a not yet fully reconstituted immunological space, and thus without the classical homeostatic control. Additionally, as the data are

Figure 5. Relative mean frequencies of CD4 T cells expressing 1, 2, 3, or 4 activation markers (adapted\(^d\) according-to-protocol cohort for cell-mediated immunity – RZV group only). M = month; RZV = adjuvanted recombinant zoster vaccine. Data labels represent percentages of mean frequencies of CD4 T cells expressing any combination of 1, 2, 3, or 4 activation markers from: CD40 ligand; interferon-γ, interleukin-2, tumor necrosis factor-α.\(^d\) Adapted denotes that for each time point presented, the corresponding according-to-protocol cohort was used.
expressed as frequencies per 10^6 CD4 T cells, the low number of total CD4 T cells may lead to a higher proportion of gE-specific CD4[2+] T cells following vaccination early post-transplant.

Underlying diseases appeared to have little impact on the humoral immune responses, except for NHBL, as these patients commonly receive immunotherapeutic agents specifically targeting B cells, such as anti-CD 20 antibodies, humoral responses were expected to be low.20 This is consistent with the blunted post-vaccination anti-gE immune response observed in a phase I/II trial of RZV in autologous HSCT recipients, which was attributed to B-cell depletion during pre-HSCT conditioning lymphoma treatment.18 In contrast, underlying diseases (including NHBL) did not appear to impact the CMI responses, which is in line with previous observations in autologous HSCT recipients.18 In NHBL patients, RZV was >60% efficacious against HZ, supportive of the belief that CMI responses are the main mechanistic driver for protection against HZ.21

Polyfunctional CD4 T-cell responses have been shown to correlate with efficacy of vaccination against human immunodeficiency virus, tuberculosis, malaria, or melanoma.23-26 Cunningham et al postulated the importance of gE-specific polyfunctional CD4 T-cell responses in driving the high efficacy of RZV against HZ in adults aged ≥50 years.20 These findings were later confirmed in the control arm of a trial evaluating immunogenicity of RZV in previous live-attenuated zoster vaccine (ZVL, Zostavax) recipients.27 In a similar evaluation, polyfunctionality was assessed in this study selecting the following four T-cell markers: IL-2, CD40L, which are the dominant activation markers shortly post-vaccination,20 and IFN-γ and TNF-α, which correlate best with vaccine-induced protection.28,29 The proportion of polyfunctional CD4 T cells increased from 1 M to 24 M post-second vaccine dose, an increase observed previously in adults aged ≥50 years.30 Of interest in the specific context of HSCT, the high proportion (>50%) of polyfunctional gE-specific CD4 T cells 1 M post-first vaccine dose may suggest the presence of gE-specific memory T cells in the transplanted grafts, which would be readily recalled by the first vaccine dose and further amplified by the second dose. It is unclear whether naïve or effector memory T cells predominate in the expansion phase after vaccination with ZVL, although it has been proposed that broadening of VZV-specific T-cell repertoire occurs through preferential expansion of infrequent T-cell clones, including recruitment of new specificities from the naïve repertoire.30 Further investigations would be required to evaluate whether this also applies to RZV.

Vaccination increased the frequency of IL-2-producing CD4 T cells. It was recently proposed that IL-2 expression at the peak of the response is required for CD4 T-cell response persistence, and this may be a key differentiator between RZV and ZVL, which may explain the observed differences in both immune responses and efficacy.28 ZVL induces an effector response profile dominated by IFN-γ, which wanes rapidly over time, while the memory T-cell profile induced by RZV, linked to IL-2 production, may explain the long-term persistence of both cellular responses and vaccine-induced protection. As in the overall study population,19 efficacy against HZ was observed for each underlying disease, although due to the small sample size and few incident HZ episodes, it was not statistically significant for some of these.

For establishing the optimal timing of vaccination in HSCT patients, several factors need to be considered, such as the long-term effect of conditioning regimens, post-transplant immune reconstitution and immunosuppressive regimens,

Plain Language Summary

What is the context?

After haematopoietic stem cell transplantation, patients have impaired immunity from conditioning chemotherapy regimens, often exacerbated by underlying diseases, putting them at high risk of developing herpes zoster. In this population, antiviral prophylaxis is the current standard of care to reduce herpes zoster risk. Vaccination provides an additional means to prevent herpes zoster. Live-attenuated vaccines are generally contraindicated in immunocompromised patients. A non-live, adjuvanted recombinant zoster vaccine (RZV, Shingrix, GSK), has been approved for use in adults ≥50 years of age in the European Union, United States, Canada, Australia, Japan, and China. This vaccine is highly efficacious at preventing herpes zoster in adults over 50 years of age, as demonstrated in large, placebo-controlled randomised trials. Importantly, Shingrix use is not contraindicated in immunocompromised conditions, and was found to be highly efficacious in adults who had recently undergone autologous haematopoietic stem cell transplant.

What is new?

In autologous haematopoietic stem cell transplant recipients in whom Shingrix has demonstrated efficacy, two doses elicited high and persistent immune responses. Data presented here further support our understanding of the impact of specific factors such as age or underlying diseases on the vaccine’s effect in the population studied, as well as the characteristics of the elicited cell-mediated immune responses.

What is the impact?

These results indicate that Shingrix, given shortly after haematopoietic stem cell transplant, can induce robust immune responses and reduce the risk of herpes zoster, even in individuals with immunosuppression due to underlying disease and/or use of immunosuppressive therapies, regardless of age or underlying disease.
and post-transplant antiviral prophylaxis. At odds with the previous observation that HSCT patients may be unable to mount a protective immune response to vaccination when given shortly after transplantation,17 this study demonstrated both high vaccine efficacy and strong immune responses after the two-dose RZV course initiated 50–70 days post-autologous HSCT.19 This is especially important to inform health care providers on timing of vaccination when protection against vaccine-preventable diseases is imperative early post-transplant such as the protection against Coronavirus Disease 2019 (COVID-19), for which treatment options and other prophylactic interventions are currently very limited. In addition, the efficacy of the evaluated RZV regimen against HZ was similar between autologous HSCT recipients who received no antiviral prophylaxis and those who received antiviral prophylaxis for up to 60 days after 1 M post-dose two,19 confirming the added benefit of vaccination early post-transplant. It also suggests that antiviral prophylaxis for the purpose of HZ prevention may be stopped at 6 M post-autologous HSCT, when the vaccine-elicited protection against HZ has already been achieved. While smaller studies showed that RZV (administered at a median 8–9 months post-transplant) was also well-tolerated in allogenic HSCT recipients, it was less immunogenic than in autologous HSCT recipients.31,32 However, administration of RZV before full immune reconstitution as well as its efficacy are yet to be evaluated in allogenic HSCT recipients.

Potential limitations of these descriptive analyses are mostly related to the small sample size and low HZ incidence in some sub-groups along with the post-hoc nature of most presented analyses, which also impact the robustness of efficacy data by underlying diseases. Details of pre-transplant conditioning treatment such as rituximab were only recorded for thirty days before transplant, and the information on the impact of specific long-lasting treatments on immune responses is incomplete. Nevertheless, the vaccine was administered 50–70 days after the autologous HSCT, when the immune system suppression was still near its maximum,33 and these descriptive analyses provide important insight for understanding the effect of the vaccine in this immunocompromised population. Although the follow-up period for efficacy was relatively short, it covered the first year post-transplant, prior to complete immunological recovery in some instances, when the risk of HZ is the highest.33

In conclusion, two RZV doses, administered 50–70 days post-transplant, induced strong and persistent humoral and CMI responses irrespective of age, and robust CMI responses irrespective of underlying diseases in adults who had undergone autologous HSCT. Glycoprotein E-specific CD4 T-cell responses were polyfunctional, and the proportion of polyfunctional CD4 T cells increased through year two post-vaccination. Post-hoc analysis of efficacy against HZ for each underlying disease was consistent with efficacy in the overall population studied,19 and vaccine efficacy was also high in NHBCL patients despite the weaker humoral immune responses. RZV, currently licensed in several countries for all adults aged ≥50 years and in Europe for adults aged ≥18 years at increased risk of HZ, has the potential to represent an additional prophylactic intervention in the care of patients after autologous HSCT, at high risk for HZ.

Acknowledgments
The authors would like to thank Agnes Mwakingwe-Omari for her support in the development of this manuscript, the study participants, investigators and study teams involved in this trial, as well as the GSK Teams: Laboratory teams who undertook the immunological assessments, Clinical Research & Development, Clinical Operations, Statisticians and Stat Analysts, Medical Data Reviewers, Safety Case Management, and Publications.

Medical writing services were provided by Alpár Pöllnitz (Modis; Cluj-Napoca, Romania; on behalf of GSK). Editorial assistance and publication coordination were provided by Sander Hulsmans (Modis; Wavre, Belgium; on behalf of GSK).

Authors’ contributions
Conceptualization: AB, MEI, HSE, TCH, LO, TCS, EAS, KMS, and FV. Validation: CA, AB, AFD, EDP, MEI, HSE, AG, TCH, LO, BS, AES, TCS, EAS, KMS, and PZ. Formal Analysis: MEI. Investigation: CA, VJA, AB, AJCB, RB, CC, AC, EDP, HSE, APGR, AGr, AGu, TCH, JJ, JYK, AL, MPZ, BS, AES, AG, TCS, UMS, EAS, KMS, FV, LYSS, and PZ. Resources: AB, EDP, HSE, AG, AL, MPZ, BS, TCS, EAS, and KMS. Writing (original draft): AB, AFD, MEI, BS, AES, EAS, and KMS. Visualization: AFD, MEI, BS, AES, EAS, and KMS. Supervision: AB, AFD, TCH, LO, and AES.

All authors contributed to the writing (review & editing) of the manuscript and approved the final submission version.

Data availability statement
Anonymized individual participant data and study documents can be requested for further research from www.clinicalstudydatarequest.com.

Disclosure statement
The authors declare the following financial relationships: During the conduct of the study, CA, and EAS report grants from the GSK group of companies (GSK); VJA reports Phase III study compensation from GSK to the research institute; and KMS reports a grant and personal fees from GSK and a grant from NIAID and NIH awarded to Duke University. Outside the submitted work, VJA reports study grants from Pfizer, and personal fees from Astellas, MSD, Pfizer, Roche, and Unimedic; AGr has served on the Advisory Boards of Bristol Myers Squibb, Gilead, MSD, Novartis, Roche, and Takeda; AGu reports personal fees from Celgene, Takeda, Janssen-Cilag, Novartis, Teva, and Jazz; and KMS reports personal fees from Kiadis Pharmaceutical, and Roche Genentech. During the design, initiation, conduct of the study and/or interpretation of the data, AB, AFD, EDP, MEI, TCH, LO, BS, and AES were employees of GSK. They also own shares in the GSK group of companies. AB, AFD, and LO are currently employed by the Bill & Melinda Gates Medical Research Institute, Mithra Pharmaceuticals, and CureVac AG, respectively; TCH and LO are inventors on a patent owned by GSK and relevant to RZV. Outside the submitted work, TCH was a paid consultant for GSK. AAA, AJCB, BB, CC, AC, HE, APGR, II, JYK, AL, MPZ, TCS, UMS, FV, LYSS, and PZ have no conflicting financial relationships to disclose. The authors declare no other non-financial relationships and activities or conflicts of interest.

Funding
This work was sponsored by GlaxoSmithKline Biologicals SA in all stages of the study conduct and analysis. GlaxoSmithKline Biologicals SA also took responsibility for all costs associated with the development and publishing of the present manuscript.
Shingrix is a trademark of the GSK group of companies. Zostavax is a trademark of Merck Sharp & Dohme Corp.

References

1. Oxman MN. Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence. J Am Osteopath Assoc. 2009;109: S13–17.
2. Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, Langan SM. Quantification of risk factors for herpes zoster: population based case-control study. BMJ. 2014;348:g2911. doi:10.1136/bmj.g2911.
3. Sahoo F, Hill JA, Xie H, Leisenring W, Yi J, Goyal S, Kimball LE, Lee I, Seo S, Davis C, et al. Herpes zoster in autologous hematopoietic cell transplant recipients in the era of acyclovir or valacyclovir prophylaxis and novel treatment and maintenance therapies. Biol Blood Marrow Transplant. 2017;23(3):505–11. doi:10.1016/j.bbmt.2016.12.020.
4. Offidani M, Corvatta L, Olivieri A, Mele A, Brunori M, Montanari M, Rupoli S, Scalari P, Leonini P. A predictive model of varicella-zoster virus infection after autologous peripheral blood progenitor cell transplantation. Clin Infect Dis. 2001;32(10):1414–22. doi:10.1093/clininf/32.10.1414.
5. Wilson A, Sharp M, Koropchak CM, Ting SF, Arvin AM. Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis. 1992;165:119–26. doi:10.1093/infdis/165.1.119.
6. Meyers JD, Flourney N, Thomas ED. Cell-mediated immunity to varicella-zoster virus after allogeneic marrow transplant. J Infect Dis. 1980;141:479–87. doi:10.1093/infdis/141.4.479.
7. Kawamura K, Hayakawa J, Akahoshi Y, Harada N, Nakano H, Kameda K, Ugai T, Wada H, Yamashiki R, Ishihara Y, et al. Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus and varicella zoster virus diseases after autologous hematopoietic stem cell transplantation. Int J Hematol. 2015;102(2):230–37. doi:10.1007/s12185-015-1810-4.
8. Zhang D, Weiss T, Feng Y, Finelli L. Duration of antiviral prophylaxis and risk of herpes zoster among patients receiving autologous hematopoietic stem cell transplants: a retrospective, observational study. Adv Ther. 2017;34:1610–21. doi:10.1007/s12128-017-0553-4.
9. Seo HM, Kim YS, Bang CH, Lee JH, Lee JY, Lee DG, Park YM. Antiviral prophylaxis for preventing herpes zoster in hematopoietic stem cell transplant recipients: A systematic review and meta-analysis. Antiviral Res 2017; 140:106-115; doi:10.1016/j.antiviral.2017.01.011.
10. Lee CJ, Savani BN, Ljungman P. Varicella zoster virus reactivation in adult survivors of hematopoietic cell transplantation: how do we best protect our patients? Biol Blood Marrow Transplant. 2018;24:1783–87. doi:10.1016/j.bbmt.2018.04.003.
11. Willis ED, Woodward M, Brown E, Popmihajlov Z, Saddier P, Annunziato PW, Halsey NA, Gershon AA. Herpes zoster vaccine live: a 10 year review of post-marketing safety experience. Vaccine. 2017;35:7231–39. doi:10.1016/j.vaccine.2017.11.013.
12. Alexander KE, Tong PI, Macartney K, Beresford R, Sheppard V, Gupta M. Live zoster vaccination in an immunocompromised patient leading to death secondary to disseminated varicella zoster virus infection. Vaccine. 2013;31:3980–93. doi:10.1016/j.vaccine.2013.05.078.
13. Lal H, Cunningham AL, Godeaux O, Chibibek R, Diez-Domingo J, Hwang S-J, Levin MJ, McElhaney JE, Poder A, Puig-Barberà J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–96. doi:10.1056/NEJMa1510118.
14. Cunningham AL, Lal H, Kovac M, Chibibek R, Hwang S-J, Diez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375:1019–32. doi:10.1056/NEJMoa1603800.
15. Lecler E, Beukelaers C, Colindres R, Curran D, De Kesel C, De Saeger J-P, Didierlaurent AM, Ledent EY, Mols JF, Mrkvan T, et al. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention. Expert Rev Vaccines. 2018;17(7):619–34. doi:10.1080/1476058X.2018.1495565.
16. Haste A, Catteau G, Eremoua A, Mrkvan T, Salau J, Volpe S, Smetsa J, Rombo L, Schwarz T, Pauksens K, et al. Immunogenicity of the adjuvanted recombinant zoster vaccine: persistence and anamnestic response to additional doses administered after primary vaccination. J Infect Dis. 2020. doi:10.1093/infdis/jiaa300.
17. Ljungman P, Cordonna C, Einsele H, Englund J, Machado CM, Storek J, Small T. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2009;44:521–26. doi:10.1038/bmt.2009.263.
18. Stadtmauer EA, Sullivan KM, Marty FM, Dadwal SS, Pananicoala GA, Sheu TC, Mossad SB, Andreadis C, Young JAH, Buadi FK, et al. A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood. 2014;124(19):2921–29. doi:10.1182/blood-2014-05-737048.
19. Bastidas A, de la Serna J, El Idrissi M, Oostvogels L, Quijet P, Lopez-Jimenez J, Vural F, Pohlreich D, Zuckerman T, Issa NC, et al. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. JAMA. 2019;322(2):123–33. doi:10.1001/jama.2019.0953.
20. Stadtmauer AL, Heineman TC, Lal H, Godeaux O, Chibibek R, Hwang S-J, McElhaney JE, Vesikari T, Andrews C, Choi WS, et al. Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older. J Infect Dis. 2018;217(11):1750–60. doi:10.1093/infdis/jiy095.
21. Weinberg A, Levin MJ, VZV T-cell-mediated immunity. Curr Top Microbiol Immunol. 2010;342:341–57. doi:10.1007/978-82-10-30_31.
22. Yri OE, Torfoss D, Hungnes O, Tiersen A, Waalen K, Nordoy T, Dudman S, Klønder A, Wader FK, Østengstad B, et al. Routine prophylactic serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood. 2011;118(26):6769–71. doi:10.1182/blood-2011-08-372649.
23. Berry N, Manousouka M, Ham C, Ferguson D, Tudor H, Mattiuazzo G, Klaver B, Page M, Stubbings R, Das AT, et al. Role of occult and post-acute phase replication in protective immunity induced with a novel live attenuated SIV vaccine. PLoS Pathog. 2016;12(12):e1006083. doi:10.1371/journal.ppat.1006083.
24. Magniolo MF, Palmer MV, Thacker TC, Vordermeier HM, McGill JL, Whelan AO, Larsen MH, Jacobs WR, Jr., Waters WR. Increased TNF-alpha/IFN-gamma/IL-2 and Decreased TNF-alpha/IFN-gamma production by central memory T cells are associated with protective responses against bovine tuberculosis following BCG vaccination. Front Immunol. 2016;7:421. doi:10.3389/fimmu.2016.00421.
25. Mordmuller B, Surat G, Lagler H, Chakravarty S, Ishizuka AS, Lalremruata A, Gmeiner M, Campo JJ, Esen M, Ruben AJ, et al. Sterile protection against human malaria by chemosensitized PISPZ vaccine. Nature. 2017;542(7642):445–49. doi:10.1038/nature21060.
26. Gross S, Erdmann M, Haendle I, Voland S, Berger T, Schultz E, Strasser E, Dankerl P, Janka R, Schliep S, et al. Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients. JCI Insight. 2017;2:e91438. doi:10.1172/jci.insight.91438.

27. Dagnew AF, Klein NP, Herve C, Kalema G, Di Paolo E, Peterson J, Salaun B, Schuind A. The adjuvanted recombinant zoster vaccine in adults aged ≥65 years previously vaccinated with a live-attenuated herpes zoster vaccine. J Infect Dis. 2020. doi:10.1093/infdis/jiaa083.

28. Levin MJ, Kroehl ME, Johnson MJ, Hammes A, Reinhold D, Lang N, Weinberg A. Th1 memory differentiates recombinant from live herpes zoster vaccines. J Clin Invest. 2018;128(10):4429–40. doi:10.1172/jci121484.

29. Panagioti E, Klenerman P, Lee LN, Van Der Burg SH, Arens R. Features of effective T cell-inducing vaccines against chronic viral infections. Front Immunol. 2018:9:276. doi:10.3389/fimmu.2018.00276.

30. Qi Q, Cavanagh MM, Le Saux S, NamKoong H, Kim C, Turgano E, Liu Y, Wang C, Mackey S, Swan GE, et al. Diversification of the antigen-specific T cell receptor repertoire after varicella zoster vaccination. Sci Transl Med. 2016;8(332):332ra346. doi:10.1126/scitranslmed.aaf1725.

31. Camargo JF, Lin RY, Natori Y, Anderson AD, Alencar MC, Wang TP, Morris MI, Komanduri KV. Reduced immunogenicity of the adjuvanted recombinant zoster vaccine after hematopoietic cell transplant: a pilot study. Blood Adv. 2020;4:4618–22. doi:10.1182/bloodadvances.2020002269.

32. Baumrin E, Izaguirre NE, Bausk B, Feeley MM, Bay CP, Yang Q, Ho VT, Baden LR, Issa NC. Safety and reactogenicity of the recombinant zoster vaccine after allogeneic hematopoietic cell transplantation. Blood Adv. 2021;5:1585–93. doi:10.1182/bloodadvances.2020003749.

33. Bosch M, Khan FM, Storek J. Immune reconstitution after hematopoietic cell transplantation. Curr Opin Hematol. 2012;19:324–35. doi:10.1097/MOH.0b013e328353bc7d.